Wednesday 31 March 2021

Patient Handling Equipment Market : The report gives immense knowledge on the competitive nature of key players 2027

 Global Patient Handling Equipment Market Analysis by MRFR is expected to be valued at USD 15,430.18 Million by 2027 at a CAGR of 8.3% during the forecast period, 2020-2027.

The advancement in patient handling equipment and expansion of healthcare infrastructure due to the COVID-19 pandemic is expected to boost the growth of the market in the forecast period.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/9986 

Market Synopsis

An increasing usage of patient handling equipment in hospitals, rehabilitation centers, and elderly care settings is expected to drive the growth of the global patient handling equipment market.

The market growth in the coming years can also be attributed to the business expansion of manufacturers through merger & acquisition and incessant launch of innovative products. For instance, in the year 2020, Invacare Corporation, a US-based long-term medical product manufacturer, announced the launch of an Invacare AVIVA FX Power Wheelchair, a front-wheel-drive wheelchair. This product launch was aimed to strengthen the company’s power mobility product portfolio.

Market USP

Growing patient population of chronic diseases and rising geriatric population are the major market influencer of the patient handling equipment market.  

Market Drivers

The rising influx of patients in the hospital due to an outbreak of COVID-19 pandemic. The critical care products including hospital beds, ventilators, and vitals monitoring devices are being used in abundance for patients suffering from COVID-19. Various companies are aiding the healthcare sector in meeting the rising demand for critical care products by increasing their manufacturing capacity. For instance, in May 2020, Stryker (US) delivered about 1,000 emergency relief beds to hospitals in Qatar. The company is also massively producing emergency relief beds, a low-cost hospital bed.      

  • Increasing geriatric and obese population
  • Risk of injuries to caregivers while manual handling of patients
  • Implementation of regulations to ensure the safety of healthcare service providers during the manual lifting procedure. For instance, according to the Office of State Human Resources (OSHR), the caregiver should do a preliminary assessment of their safety & health risks before any manual handling operation and take appropriate steps to lower the risks of patient handling. Also, manual handling operations should be avoided as far as it is reasonably practicable.
  • A growing number of road accidents
  • Growing usage of ceiling lifts in hospitals

Market Restraints

  • Low skilled professionals for the efficient operation of the patient handling equipment.

Segmentation

By Product

  • Patient Transfer Devices: This segment is likely to hold the largest share owing to the growing number of obese patients. This segment is further fragmented into patient lifts, air-assisted lateral transfer mattresses, sliding sheets, and accessories. Patient transfer devices aid in long and short distance transfer of patients depending on the requirement. Also, these products provide caregivers reduced risk of injuries while patient handling and are time efficient. According to National Public Radio, every year about 35,000 nursing professionals experience back and body injuries during patient handling in the US region.
  • Medical Beds: This segment is further segmented into manual beds, electric beds, and semi-electric beds. The rising number of COVID-19 patients has influx the demand for medical beds in the forecast period. Also, the growing geriatric population base susceptive to chronic disease will be driving the growth of the segment. For instance, in 2019, according to the United Nations, globally there were about 703 million people aged 65 or over.
  • Mobility Devices: This segment is further segmented into wheelchairs & mobility scooters, and ambulatory aids. The increasing cases of disability are expected to propel the demand for mobility devices. The ambulatory aid equipment provides support, stability, and balance for patients. The ambulatory aid segment includes equipment such as crutch, cane walking, walker, and others.
  • Bathroom & Toilet Assist Equipment: These segments include bathroom assist products such as commodes, bath aids, handgrips, bath lifts, shower chairs, and others. Easy availability in online stores is likely to propel the growth of the segment.
  • Stretchers & Transport Chairs: These are used in carrying patients from one place to another, within and outside of a healthcare facility. The advancement in stretchers & transport chairs has been enabling clinicians in providing patients with proper emergency assistance.

By Application

  • Acute & Critical Care: This segment is likely to hold the largest share owing to high prevalence rate cardiovascular diseases, viral infection, and other acute diseases. For instance, in 2017, according to the Centers for Disease Control and Prevention (CDC), about 18.2 million adult population aged 20 or older were suffering from coronary heart disease in the US region.
  • Long Term Care: This segment is likely to be the fastest-growing segment owing to the growing prevalence of target diseases such as tuberculosis, Alzheimer’s disease, tetanus, and others. For instance, according to Alzheimer's Association, in the US, about 5.8 million people aged 65 or above were suffering from Alzheimer’s dementia in 2019 and 5.7 million in 2018.
  • Mobility Assistance: The growth of this segment can be attributed to the growing incidence rate of diseases such as arthritis and Parkinson’s.  For instance, according to Parkinson's Foundation, every year about 60,000 of the American population are diagnosed with Parkinson’s disease. This disease is characterized by stiffness, slowed movement, tremors, and impaired balance. The mobility assistance devices improve balance and provide support to patients suffering from Parkinson’s disease. Also, the rising elderly population is expected to drive the growth of the segment.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/patient-handling-equipment-market-9986 

Medical Payment Fraud Detection Market Current Trends, SWOT Analysis, Strategies, Industry Challenges, Business Overview and Forecast Research Study 2027

 Market Forecast

Global Medical Payment Fraud Detection Market Forecast is expected to hold a value of USD 5786.44 Million by 2027 and is expected to register a growth of 25.2% from 2020 to 2027.

Market Synopsis

Medical fraud is increasingly apperceived as one of the social concerns. Healthcare fraud varies, but generally, it involves filing dishonest health claims for profit. The combination of fear loosened healthcare regulations, and expected stimulus payments in response to the COVID 19 pandemic could unleash an unprecedented surge of healthcare scams and fraud. The rising number of patients opting for health insurance, increasing pressure of fraud, and abuse on healthcare spending are the key factors that are expected to drive the market growth. For instance, according to the Centers for Disease Control and Prevention, 2018, report, 65.1% of people under the age of 65, in the US opted for private healthcare insurance. Moreover, a large number of fraudulent activities, rising healthcare expenditures, and growing pressure to increase operational efficiency and reduce healthcare spending are also expected to boost market growth.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/9778 

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas region held the largest market in 2020, owing to the increasing number of patients opting for health insurances. For Instance, according to the Centers for Disease Detection and Prevention, in 2018 report, 25.5% people under age of 65 opted for public health insurance in the United States. The medical payment fraud detection market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European medical payment fraud detection market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, Italy, Spain, the UK and the rest of Western Europe. The medical payment fraud detection market in Asia-Pacific has been segmented into Japan, China, India, Australia, South Korea, and the rest of Asia-Pacific. Due to large number of fraudulent activities, the market in Asia-Pacific is expected to be the fastest-growing. The medical payment fraud detection market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

Global Medical Payment Fraud Detection Market has been segmented based on the Type, Component, Delivery Model, Source of Services, and End User.

Based on Type, the global medical payment fraud detection market has been segmented into descriptive analytics, predictive analytics, and prescriptive analytics. Descriptive analytics forms the base for the effective application of predictive and prescriptive analytics.

On the basis of components, the market has been segmented into services and software. Software fraud detection is expected to hold a major market share.

Based on the delivery model, the market has been segmented into on-premise and cloud-based. The cloud-based fraud detection market is expected to gain traction during the forecast period.

On the basis of the source of service, the market has been segmented into in-house and outsourced.

The market based on end-user has been segmented into private insurance payers, public/ government agencies, and third-party service providers.

Key Players

Some of the key players in the global medical payment fraud detection market are LexisNexis Risk Solutions (US), International Business Machines Corporation (US), Optuminsight (US), OSP Labs (India), DXC Technology Company (US), UnitedHealth Group (US), SAS Institute (US), Fair Issac Corporation (US), EXL Service Holdings, Inc. (US), CGI GROUP (Canada).

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/medical-payment-fraud-detection-market-9778 

Menopause Treatment Market: Drivers, Restraints, Opportunities, and Threats (2020-2027)

 

Market Overview

Market Research Future (MRFR) suggests in its new exhaustive study that the Menopause Treatment Market can expect to touch USD 15,456.3 Million by 2027. It is quite possible for the market size to expand at a lucrative rate of 6.18% over the assessment period (between 2020 and 2027).

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/4579 

Menopause causes uncomfortable symptoms, such as hot flashes, vaginal dryness, and weight gain and menopause treatments such as hormonal and non-hormonal treatments help to relieve these symptoms. Over the years, major market players in the menopause treatment are focusing on various growth strategies such as product launches, product advancements and expansions to cater to the growing needs for patients seeking treatment for menopause symptoms. For instance, in April 2019, Otsuka Pharmaceutical launched EQUELLE, a non-prescription, non-hormonal supplement to alleviate the frequency of hot flashes and muscle aches associated with menopause in the US. Such strategies push the demand for branded as well as generic menopausal drugs, thus promising huge growth for the industry.

Segment Analysis

The global menopause treatment market is segmented based on treatment and distribution channel.

The global menopause treatment market based on the treatment has been segmented into hormonal treatment and non-hormonal treatment. The hormonal treatment segment is further segmented into estrogen, progesterone, and combination. The non-hormonal treatment is further segmented into anti-depressants and others.

Based on distribution channel, the menopause treatment market is segmented into hospital pharmacies, retail pharmacies, and online stores.

Regional Analysis

The global menopause treatment market, based on region, has been divided into the Americas, Europe, Asia-Pacific, and Middle East & Africa.

The Americas has been segmented into North America and Latin America, with the North America market further divided into the US and Canada. The Americas led the market and accounted for the largest share in 2019 owing to the increasing product approvals and high uptake of new technology.  For instance, in July 2017, AMAG Pharmaceuticals, Inc. (US) launched Intrarosa (prasterone) for the treatment of moderate to severe dyspareunia a symptom of vulvar and vaginal atrophy (VVA), due to menopause. Thus, such strategies employed by major players aid in the increased growth rate for the Americas menopause treatment industry.

The European menopause treatment market has been further segmented into Western Europe and Eastern Europe. The Western Europe menopause treatment market has further been classified into Germany, France, the UK, Italy, Spain, and the rest of Western Europe. Europe follows the Americas in the global menopause treatment market. The increasing inclination of companies towards female technology (femtech) is boosting the growth of the menopause treatment market in European countries. Many digital health start-ups have identified this opportunity and are offering B2C digital health tools, such as mobile apps, to guide menopausal women through this phase with lifestyle intervention tips and online telehealth consultations. As a result, the region is expected to show significant growth in the menopause treatment market.

The menopause treatment market in Asia-Pacific has been segmented into China, India, Japan, South Korea, Australia, and the rest of Asia-Pacific. Asia-Pacific is expected to register the highest growth rate over the forecast period from 2020 to 2027. This is owing to the growing penetration of the women’s health sector, increasing awareness about the betterment of the women’s health, and the growing number of educational campaigns related to the benefits of hormone replacement therapy in China, Japan, India, and Australia.

The Middle East & Africa menopause treatment market is segmented Saudi Arabia, the United Arab Emirates (UAE), Oman, Kuwait, Qatar, and the rest of the Middle East & Africa. The negative connotation of menopause has resulted in a negative attitude towards menopause in premenopausal women. However, with the increasing awareness created by private companies, the scenario is expected to change in the next ten years.

Key Players

MRFR recognizes the following companies as the Key Players in the Global Menopause Treatment Industry Applications — Novo Nordisk A/S (Denmark), Pfizer Inc. (US), Allergan (Ireland), Eli Lily and Company (US), Emcure Pharmaceuticals Ltd (India), Novartis AG (Switzerland), Cipla Inc. (India), Teva Pharmaceuticals (Israel), Merck & Co., Inc. (US), Abbott Laboratories (US).

Key Findings of the Study

  • The Global Menopause Treatment Market is estimated to reach USD 15,456.3 Million by 2027 at a CAGR of 6.18% during the assessment period of 2020 to 2027
  • The Americas accounted for the largest share of the global menopause treatment market due to the existence of prominent players in the US, high uptake of hormonal therapy, and product clearances from regulatory authorities
  • Based on treatment, the hormonal treatment segment accounted for the largest market share of 74.6% in 2019
  • On the basis of distribution channel, the hospital pharmacies segment was the fastest growing with the CAGR of 6.59% during the assessment period

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/menopause-treatment-market-4579 

Nebulizers Market – Functional Survey 2027

 Global Nebulizers Market Forecast 2027 expected to hold a value of USD 1,629.7 Million and is expected to register a growth of 7.32% from 2020 to 2027.

Nebulizers Market Synopsis

Nebulizers are a device that has the capability of changing a medication from a liquid to a mist so that it can be inhaled into the lungs. High demand for respiratory devices, including nebulizers, due to the outbreak of COVID-19 globally, growing need for rescue medication, increasing prevalence of respiratory diseases, and rising demand for home healthcare devices are the key factors that are expected to drive the market growth. Moreover, the growing geriatric population, increasing consumption of alcohol, tobacco, cigarettes, and other such products may lead to respiratory diseases, and the rising number of initiatives taken by the government as well as the private organizations are also expected to boost the market growth.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/9586 

Key Players

However, the loss of drug during nebulization procedures, availability of various substitutes for nebulizers, and side effects of nebulizer solutions are expected to restrain the growth of the global nebulizers market.

Several market players such as OMRON Healthcare, Koninklijke Philips N.V., and B. Braun Melsungen AG, among others currently dominate the global nebulizers market. The key players are involved in awareness campaigns, product approvals, mergers, and strategic collaborations to strengthen their market positions. For instance, in April 2020, B. Braun Melsungen AG received the Food and Drugs Administration (FDA) emergency use authorization for using its infusion pumps with nebulizers to treat COVID-19 patients.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas region held the largest market in 2019, owing to the rising demand for respiratory diseases in the region. The nebulizers market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European nebulizers market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The nebulizers market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. Due to the increasing incidence rate of respiratory diseases, the market in Asia-Pacific is expected to be the fastest-growing. The nebulizers market in the Middle East & Africa has been divided into the Middle East and Africa.

The Global Nebulizers Market has been Segmented Based on the Type, Usage, Portability, and End User.

Based on the Type, the global nebulizers market has been segmented into mesh, jet, and ultrasonic. The mesh segment is further divided into active and passive. The jet segment is expected to hold the largest market share owing to its low cost as compared to other types of nebulizers.

On the basis of usage, the market has been segmented into reusable and disposable. The disposable nebulizers are expected to hold a major market share owing to their growing popularity amongst the users.

Based on the portability, the market has been segmented into tabletop and portable. The portable nebulizers market is expected to grow at the fastest CAGR owing to its ease and convenience of use.

The market based on end-user has been segmented into hospitals & clinics, home care, and others. The hospitals and clinics segment is expected to hold the largest market share owing to the larger patient footfall in hospitals.

Key Players

Some of the key players in the global nebulizers market are OMRON Healthcare (Japan), Koninklijke Philips N.V. (Netherlands), PARI (US), Vectura Group plc (UK), Rossmax International Ltd (Taiwan), Briggs Healthcare (US), GF Health Products, Inc. (US), Beurer GmBH (Germany), Agilent Technologies, Inc. (US), Drive DeVilbiss Healthcare (US), Invacare Corporation (US), and B. Braun Melsungen AG (Germany).

Segmentation

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/nebulizers-market-9586 

ETMF Systems Market – Insights on Upcoming Trends 2027

 Global eTMF Systems Market is expected to reach a value of USD 1825 Million by 2025, at a CAGR of 13.11% during the assessment period of 2019 to 2025.

Electronic Trial Master File Systems Market Synopsis

The pharmaceutical, as well as the biotechnology companies, face a major challenge to maintain a central repository for the storage of clinical trial documents for use in regulatory submissions. Therefore, there emerges a need to store all the data produced by these companies effectively. As a result, software companies have developed electronic trial master file systems that aid these companies as well as the contract research organizations in systemized storage of files. Moreover, in comparison to the traditional storage systems, electronic trial master file systems facilitate content classification and easier interoperability in clinical trial operations. Therefore, the major companies are continuously involved in new product launches to gain a competitive edge over the other players.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8772 

Key Players

Some of the Global Electronic Trial Master File (eTMF) Systems Market Key Players are Aurea, Inc. (US), Covance Inc. (US), ePharmaSolutions (US), MasterControl, Inc. (US), Oracle (US), Phlexglobal (UK), SureClinical Inc. (US), TransPerfect (US), Veeva Systems (US), and Wingspan (IQVIA) (US).

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas held the maximum share in the base year 2018, owing to the presence of established key players in countries such as the US and Canada. The eTMF systems market in the Americas has been segmented into North America and Latin America, with the North American market divided into the US and Canada. The European eTMF systems market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The eTMF systems market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The eTMF systems market in this region is anticipated to be the fastest-growing during the assessment period due to the increased adoption rate of eTMF software and services in the Asian countries. The eTMF systems market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The Global eTMF Systems Market has been segmented based on Component, Deployment Mode, and End User.

The global eTMF systems market has been segmented, based on the component, into software and services. The software segment is expected to hold the majority share of the market owing to the increasing number of solution launches by the prominent players in recent years. The services segment is expected to be the fastest-growing due to the increasing uptake of eTMF services by pharmaceutical and life science companies.

The global eTMF systems market, based on deployment model, has been segmented into cloud/web-based, and on-premise. The cloud/web-based segment holds the maximum share owing to the technological advancements in cloud-based solutions in recent years.

The end-users of the market are pharmaceutical and biotechnology companies, contract research organizations, and others. The increasing number of clinical trials conducted by pharma firms is leading to the market size of the pharmaceutical and biotechnology companies’ segment.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/etmf-systems-market-8772 

Tuesday 30 March 2021

Cell Lysis and Disruption Market Top Companies, Business Insights, Growth, Global Market Share, Global Market Size, Trends, Sales, Revenue, Forecast and Detailed Analysis 2027

 Market Forecast

Global Cell Lysis & Disruption Market is expected to cross USD 5.7 Billion by 2025 at a CAGR of 8.6%.

Market Synopsis

Cell lysis & disruption is a method in which the cell membrane is broken down in order to extract the nucleic acids or proteins from a cell. The choice of cell lysis method depends on the type of cells, concentration, application (post-processing) and efficiency required. The demand for cell lysis & disruption is increasing due to the rising number of research & development activities in the biotechnology industry. This is majorly attributed to the increasing adoption of biotech processes in the pharmaceutical, agricultural sector.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8358 

Market Influencers

The rising focus on personalized medicine would directly drive the growth of the global cell lysis & disruption market. Strategic initiatives, mergers & acquisitions, partnerships, agreements, product launches, government approvals, and expansion of manufacturing facilities by major competitors are expected to positively affect market growth during the forecast period.   

Regional Analysis

On a regional basis, the Americas is anticipated to dominate the global cell lysis & disruption market owing to the growing clinical R&D budgets by both governments as well as public and private organizations in the pharmaceutical and biotech sector and increasing demand for novel therapeutics in the region.  Additionally, the rising prevalence of geriatric population along with various chronic diseases is contributing to the growth of this market. According to a report by the Population Reference Bureau, the number of older population (aged 65 and above) will rise to nearly 24% from 15% by 2060. Europe is expected to hold the second-largest position in the global cell lysis & disruption market owing to the presence of a strong academic & research base and availability of funding for research in the European countries. Moreover, rising healthcare expenditure is boosting the market in this region. Asia-Pacific is anticipated to be the fastest-growing region is due to the growing interest of major key players in emerging markets and rapidly developing healthcare infrastructure in this region. The Middle East & Africa has the least share of the global cell lysis & disruption market. Moreover, the major market share of the region is expected to be held by the Middle East region owing to the increasing government initiatives for the healthcare sector.  

Segmentation

The global cell lysis & disruption market has been segmented into technique, product, cell type, and end user.

By technique, the market has been segregated into reagent based and physical disruption. The reagent based segment has been further sub-segmented into detergent and enzymatic. The physical disruption further divided into mechanical homogenization, ultrasonic homogenization, pressure homogenization, and temperature treatments

By product, the market has been bifurcated into consumables and instruments. The consumables segment is estimated to hold major market share in the market due to the rise in funding of cell based research. Consumables has been further divided into reagent and kits, beads and disposables. The instrument segment has been further categorized as sonicators, homogenizers, French press, microfluidizer, and others.  

On the basis of cell type, the global cell lysis & disruption market has been classified as mammalian cells, microbial cells, and others.

The global cell lysis & disruption market, by end user, has been divided into research laboratories and institutes, pharmaceutical and biotechnology companies, and others.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/cell-lysis-disruption-market-8358 

G-Protein Coupled Receptors Market Size, Share, Top Region, Key Players, Application, Status and Forecast 2027

 Market Forecast

G-Protein Coupled Receptors Market is expected to cross USD 4,200 Million by 2025 at a CAGR of 7.1% during the forecast period.

The growing use of G-protein coupled receptors in medicate disclosure and advancement forms is set to drive the demand of G protein-coupled receptors.

G-protein coupled receptors are most commonly prescribed for the treatment of cardiovascular disease, oncology, immunology, respiratory system, central nervous system (CNS), and others. GPCRs (G-protein coupled receptors) play a physiological role in the regulation of cardiac function in both health and disease and thus represent one of the largest class of surface receptors targeted by drugs.

Browse Sample of the Report @ https://www.marketresearchfuture.com/sample_request/8356 

The growth of global G protein coupled receptors market is driven by various factors such as growing use of G protein combined receptors in medicating disclosure and advancement forms, increasing the number of drugs under clinical and preclinical studies that target these receptors. However, the high cost involved in the maintenance of GPCR cell lines is expected to curb the growth of the global G protein coupled receptor market.

Several market players currently dominate the global G protein coupled receptors market. The key players are involved in product launches and strategic collaborations to strengthen their market positions.

Regional Analysis

The market has been divided, by region, into the Americas, Europe, Asia-Pacific, and the Middle East & Africa. The Americas is expected to be the largest market owing to the presence of a large number of approved drugs that target G-protein coupled receptors. The G protein coupled receptors market in the Americas has further been branched into North America and Latin America, with the North American market divided into the US and Canada. The European G protein coupled receptors market has been categorized as Western Europe and Eastern Europe. The Western European market has further been classified as Germany, France, the UK, Italy, Spain, and the rest of Western Europe. The G protein coupled receptors market in Asia-Pacific has been segmented into Japan, China, India, South Korea, Australia, and the rest of Asia-Pacific. The rising number of approved drugs that target GPCRs has boosted the growth of the G protein coupled receptors market, the market in Asia-Pacific is expected to be the fastest-growing. The G protein coupled receptor market in the Middle East & Africa has been divided into the Middle East and Africa.

Segmentation

The global G protein coupled receptors market has been segmented based on the product, assay type, and application.

The market, based on product, has been divided into cell lines, detection kits, cell culture reagents, ligands, and others. The detection kits segment is likely to be the fastest during the review period as they are ready to use kits that includes all cells and reagents to perform functional GPCRs assay in live cells thus driving the growth of the global G protein coupled receptor market.

The global G protein coupled receptor market has been bifurcated, on the basis of assay type, into functional calcium assays, cAMP functional assays, cGMP assays, GTP gamma S binding assays, ß-Arrestin Functional Assays, internalization assays, and others. Calcium functional assays are the fastest segment as it has numerous advantages such as user configurability, ease in the estimation of calcium flux thus driving the growth of this segment in the GPCR market.

The global G protein coupled receptors market has been segmented, based on application into the cardiovascular system, oncology, immunology, respiratory system, central nervous system, and others. The cardiovascular system is the largest segment as angiotensin II, and β-adrenergic receptors provide therapy for a wide range of cardiovascular disease such as heart failure. Approximately 17.9 million people die each year from cardiovascular disease thus rising the growth of G protein coupled receptor market.

Key Players

Some of the key players in the global G protein coupled receptor market are Thermo Fisher Scientific, Inc., Cisbio, Promega Corporation, Abcam PLC, PerkinElmer Inc., Merck Group, HD Biosciences Co., Ltd, QIAGEN, Enzo Life Sciences, and Inc.BD.

Browse More Details of the Report @ https://www.marketresearchfuture.com/reports/g-protein-coupled-receptors-market-8356